Abstract
As an MHC class I protein, the disease association of HLA-B27 with inflammatory arthritis has been widely assumed to imply a role for the T cell antigen receptor (TCR) in disease. However, in addition to their classical antigen-presenting role, HLA class I proteins are recognised by members of the killer immunoglobulin receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR / ILT / LIR) families. Unusual properties of HLA-B27 include an ability of free heavy chains (FHC) to reach the cell surface in the absence of β2m and to maintain their peptide-binding groove in vitro. This review describes immunomodulatory receptors that recognise HLA class I, and the recognition of HLA-B27 in both the classical β2m-associated and β2m-independent forms by members of the KIR and LILR families. Alternative recognition of different forms of HLA-B27 by leukocyte receptors could influence the function of cells from both innate and adaptive immune systems, and may indicate a role for various leukocyte populations in HLA-B27-associated inflammatory disease.
Keywords: hla-b27, spondyloarthropathy, ankylosing spondylitis, heavy chain, hc-b27, tcr
Current Molecular Medicine
Title: Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors
Volume: 4 Issue: 1
Author(s): Rachel L. Allen and John Trowsdale
Affiliation:
Keywords: hla-b27, spondyloarthropathy, ankylosing spondylitis, heavy chain, hc-b27, tcr
Abstract: As an MHC class I protein, the disease association of HLA-B27 with inflammatory arthritis has been widely assumed to imply a role for the T cell antigen receptor (TCR) in disease. However, in addition to their classical antigen-presenting role, HLA class I proteins are recognised by members of the killer immunoglobulin receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR / ILT / LIR) families. Unusual properties of HLA-B27 include an ability of free heavy chains (FHC) to reach the cell surface in the absence of β2m and to maintain their peptide-binding groove in vitro. This review describes immunomodulatory receptors that recognise HLA class I, and the recognition of HLA-B27 in both the classical β2m-associated and β2m-independent forms by members of the KIR and LILR families. Alternative recognition of different forms of HLA-B27 by leukocyte receptors could influence the function of cells from both innate and adaptive immune systems, and may indicate a role for various leukocyte populations in HLA-B27-associated inflammatory disease.
Export Options
About this article
Cite this article as:
Allen L. Rachel and Trowsdale John, Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors, Current Molecular Medicine 2004; 4 (1) . https://dx.doi.org/10.2174/1566524043479329
DOI https://dx.doi.org/10.2174/1566524043479329 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Antiplatelet Effects of Bioactive Compounds Present in Tomato Pomace
Current Drug Targets Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Comparison of Clinical Features at the Onset of Takayasu’s Arteritis According to Age and Sex
Current Vascular Pharmacology Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Pathological Features of Antibody-Mediated Rejection
Current Drug Targets - Cardiovascular & Hematological Disorders Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Comparative Analysis of the Rabbit Endothelial Progenitor Cells from Bone Marrow and Peripheral Blood Treated with Selenium Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Predictors of Avascular Necrosis in a Cohort of Egyptian Systemic Lupus Erythematosus Patients: Retrospective Two Centers Study
Current Rheumatology Reviews Editorial (Thematic Issue: Cardio-Metabolic Complications: Current Perspective and Future Developments)
Current Pharmaceutical Design From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry